Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>Azitra is developing genetically engineered bacteria for therapeutic use in dermatology.</li><li>The company possesses a microbial library of 1,500 unique bacterial strains that are candidates for a variety of indications.</li><li>Azitra's lead candidate is ATR-12 for the rare disease Netherton syndrome (NS).</li></ul>

Azitra is developing genetically engineered bacteria for therapeutic use in dermatology.The company possesses a microbial library of 1,500 unique bacterial strains that are candidates for a variety of indications.Azitra's lead candidate is ATR-12 for the rare disease Netherton syndrome (NS).

AZTR: ATR-04 Trial to Dose 1st Patient Mid-2025

<ul><li>Azitra is developing genetically engineered bacteria for therapeutic use in dermatology.</li><li>The company possesses a microbial library of 1,500 unique bacterial strains that are candidates for a variety of indications.</li><li>Azitra's lead candidate is ATR-12 for the rare disease Netherton Syndrome (NS).</li></ul>

Azitra is developing genetically engineered bacteria for therapeutic use in dermatology.The company possesses a microbial library of 1,500 unique bacterial strains that are candidates for a variety of indications.Azitra's lead candidate is ATR-12 for the rare disease Netherton Syndrome (NS).

United States

Azitra Inc operates as a clinical biopharmaceutical company. The Company focuses on developing innovative therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. Azitra serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Azitra (AZTR US)

AZTR: ATR-01 Data Presented

Azitra is developing genetically engineered bacteria for therapeutic use in dermatology. The company possesses a microbial library of 1,500 unique...

Zacks Small Cap Research

AZTR: Second Quarter Update

Azitra is developing genetically engineered bacteria for therapeutic use in dermatology. The company possesses a microbial library of 1,500 unique...

Zacks Small Cap Research

AZTR: ATR-04 Trial to Dose 1st Patient Mid-2025

Azitra is developing genetically engineered bacteria for therapeutic use in dermatology. The company possesses a microbial library of 1,500 unique...

Zacks Small Cap Research

AZTR: Netherton Topline By Year-End

Azitra is developing genetically engineered bacteria for therapeutic use in dermatology. The company possesses a microbial library of 1,500 unique...

Zacks Small Cap Research

AZTR: Planning 2nd Site for ATR-12 Trial

Azitra is developing genetically engineered bacteria for therapeutic use in dermatology. The company possesses a microbial library of 1,500 unique...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)